Recently, two clinical trials that used anti-VEGF and anti-VEGFR2 antibodies, respectively, as add-on therapies to ICI monotherapy in HCC have shown encouraging results (Table 2). This evidence concerns the gene VEGFA and hepatocellular carcinoma.